At a Glance: Orforglipron + CBD Oil
Interaction Summary| Parameter | Detail |
|---|---|
| GLP-1 Medication | Orforglipron — brand names: Foundayo |
| Drug Class | Oral GLP-1 receptor agonist (small molecule) |
| Approval Status | FDA-approved April 1, 2026 |
| Cannabis Method | CBD Oil — Oral CBD Drops, Softgels, High-CBD Tinctures |
| Absorption Route | GI tract → liver (oral softgels/capsules); partial sublingual (drops held under tongue) |
| Normal Onset | 30–90 minutes (oral); 15–45 min (sublingual hold) |
| Onset on GLP-1 | Oral: delayed 2–4+ hours on GLP-1; sublingual component less affected |
| GLP-1 Interaction Risk | 🔵 Moderate — Moderate — GI delay + downstream CYP interaction with co-medications |
| Primary Mechanism | GLP-1 gastric emptying delay does not affect pulmonary absorption; pharmacodynamic effects still apply |
The Mechanism: Why Orforglipron Affects CBD Oil Differently
Clinical PharmacologyGLP-1 delays CBD oil absorption — and CBD raises levels of co-medications
Oral CBD oil products — swallowed drops, softgels, capsules — are absorbed through the GI tract and processed by the liver. GLP-1 gastric slowing delays this absorption in the same way it delays edibles and other oral cannabis. Additionally, CBD is a potent inhibitor of CYP450 liver enzymes (CYP2C9, CYP2D6, CYP3A4). While the GLP-1 medication itself is generally not significantly CYP-metabolized, the other medications commonly taken alongside GLP-1 therapy — statins, blood pressure drugs, antidepressants — often are. CBD oil does not merely interact with the GLP-1 drug; it interacts with the entire medication stack. FDA Foundayo PI NIH NCCIH
For Rybelsus or Foundayo patients: oral CBD oil taken near the GLP-1 medication's dosing window competes with it in the GI tract. Rybelsus requires an empty stomach and only 4 oz water for 30 minutes before eating. Foundayo has similar fasting requirements. Take oral CBD at a clearly separate time from these oral GLP-1 medications.
Orforglipron (Foundayo) activates GLP-1 receptors in the gut and brainstem, slowing the rate at which the stomach empties its contents into the small intestine. This mechanism is intentional and contributes to the medication's appetite-suppressing effects and post-meal blood glucose control. For inhaled cannabis, this mechanism is irrelevant because lung absorption bypasses the GI tract entirely. FDA Foundayo PI
CBD affects co-medications taken alongside GLP-1 therapy
The most clinically significant CBD oil concern in GLP-1 patients is not the CBD-GLP-1 interaction itself — it is CBD's effect on the other drugs in the same patient's medication regimen. A patient on Ozempic, atorvastatin, lisinopril, and sertraline who adds daily CBD oil is introducing CYP enzyme inhibition that may raise levels of all three co-medications simultaneously. This is the context in which CBD oil review with a pharmacist or prescriber is most important.
About Orforglipron: Drug Profile
Medication Context| Detail | Information |
|---|---|
| Generic Name | Orforglipron |
| Brand Names | Foundayo |
| Drug Class | Oral GLP-1 receptor agonist (small molecule) |
| Approved Uses | Type 2 diabetes and weight management |
| Administration | Oral daily pill (first oral small-molecule GLP-1 agonist — non-peptide) |
| Approval Status | FDA-approved April 1, 2026 |
Orforglipron (Foundayo) is itself an oral medication processed through the GI tract — the first oral small-molecule GLP-1 agonist. This creates a unique concern not present with injectable GLP-1s: oral cannabis products and Foundayo are both competing for GI processing simultaneously. Foundayo has specific administration requirements (empty stomach, only water for 30+ minutes before) that oral cannabis products directly conflict with.
Practical Guidance for Orforglipron Patients Using CBD Oil
Clinical Recommendations- GLP-1 gastric slowing delays oral CBD oil absorption — therapeutic effect takes longer and may be less predictable
- CBD inhibits CYP3A4, CYP2C9, and CYP2D6 — review all co-medications for interaction risk at interactsafe.com
- For Rybelsus or Foundayo: take oral CBD at a separate time from the oral GLP-1 to avoid GI timing conflict
- CBD softgels and capsules behave identically to edibles from a GLP-1 gastric slowing standpoint
- Sublingual CBD oil (held 60–90 sec) provides faster and more predictable onset than swallowed CBD on GLP-1 medications
Frequently Asked Questions
Orforglipron + CBD Oil CannabisCan I take CBD oil while on Orforglipron (Foundayo)? ▼
CBD oil can be used alongside Orforglipron (Foundayo), but requires awareness of two separate concerns. First, Orforglipron's gastric slowing delays oral CBD oil absorption — therapeutic effect arrives later and less predictably than without GLP-1 medication. Second, CBD inhibits CYP450 liver enzymes (CYP2C9, CYP2D6, CYP3A4), which may raise plasma levels of other medications you take alongside Orforglipron — particularly statins, blood pressure drugs, and antidepressants. Use the InteractSafe checker to review your complete medication list for CBD interactions.
Does CBD oil interact with Foundayo? ▼
The direct pharmacokinetic interaction between CBD and Orforglipron (Foundayo) is generally low — GLP-1 receptor agonists are not primarily CYP-metabolized, so CBD enzyme inhibition does not significantly raise Orforglipron drug levels. The more relevant interaction is pharmacodynamic and contextual: Orforglipron's gastric slowing delays CBD absorption, and CBD's CYP inhibition affects other medications in the same patient's regimen. For patients on Orforglipron who also take warfarin, statins, or antidepressants, CBD oil creates a downstream interaction concern with those co-medications.
How should I time CBD oil doses with Orforglipron? ▼
Timing CBD oil with Orforglipron (Foundayo) depends on the form. For injectable GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Saxenda, Byetta, Bydureon), CBD oil timing does not need to be coordinated with the injection, but the CBD oil's own absorption will be delayed by Orforglipron's gastric slowing regardless of when it is taken. For oral GLP-1 medications (Rybelsus, Foundayo), take CBD oil at a clearly separate time — these oral GLP-1 pills have strict fasting requirements that oral CBD oil conflicts with. Morning GLP-1, evening CBD oil, for example.
View credentials → · Verify NPI →
Primary Sources
- FDA. Foundayo (orforglipron) Prescribing Information. NDA 217564. Approved April 2026. Pharmacodynamics section: gastric emptying delay. Drug interactions section.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217564lbl.pdf - NIH NCCIH. "Cannabis (Marijuana) and Cannabinoids: What You Need To Know." Updated December 2021. Drug interactions and cannabis pharmacokinetics by route of administration.
https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know - FDA. Epidiolex (cannabidiol) Prescribing Information. NDA 210365. CYP2C9, CYP2D6, CYP3A4 inhibition by CBD — relevant to co-medications taken alongside GLP-1 therapy.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210365s006lbl.pdf - NIH MedlinePlus. Orforglipron Drug Information. National Library of Medicine. Pharmacodynamics, gastric emptying, and drug interaction sections.
https://medlineplus.gov/druginformation.html
Check Your Full Medication List
Taking Orforglipron plus other medications or supplements? Use InteractSafe to review your complete combination.
Orforglipron + Cannabis Full Profile →Or open the full interaction checker · Free · No account required · Not medical advice